TG Therapeutics, Inc. (NASDAQ:TGTX) Sees Neutral Rating and Increased Price Target from Goldman Sachs

Core Insights - TG Therapeutics is focused on developing treatments for B-cell diseases, with its flagship product BRIUMVI targeting relapsing multiple sclerosis (RMS) [1] Financial Performance - Goldman Sachs updated its rating for TG Therapeutics to Neutral, maintaining a hold recommendation, with the stock price at $29.54 and a raised price target from $37 to $39 [2][6] - TG Therapeutics projects FY25 revenue to reach approximately $616 million, an 87% increase from $329 million in FY24, and anticipates FY26 revenue between $875 million and $900 million [3][6] - BRIUMVI is expected to contribute around $594 million in product revenue for FY25, with FY26 projections ranging from $825 million to $850 million [4][6] Market Position - Despite a 7.7% decline in shares over the past year, TG Therapeutics remains optimistic about long-term revenue growth driven by BRIUMVI's commercial performance and market share capture [5]